Monsanto Buys Rights to CRISPR

The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

By | September 27, 2016

Monsanto buys CRISPR licenseWIKIMEDIA, BIDGEEMonsanto is taking genetically engineered crops to the next level, buying a license from the Broad Institute of Harvard University and MIT to use the CRISPR/Cas9 gene-editing technology. The agreement, which is nonexclusive, is the first time the Broad has issued a license for the agricultural use of CRISPR.

“Getting more productivity out of less acres with less inputs is clearly a critical thing for humanity,” Tom Adams, head of biotechnology at Monsanto, told New Scientist. “And gene editing is another tool that can help us accelerate that.”

The financial details of the agreement were not disclosed, though there are some limitations on the use of the license. For example, Monsanto cannot use CRISPR technology to develop gene drives or to make sterile (“terminator”) seeds, which require that farmers buy new seeds every year, STAT News reported. Moreover, the licensed technology cannot be used to modify tobacco for commercialization.

Two other companies, DuPont Pioneer and Calyxt, are currently using CRISPR gene-editing techniques for agricultural applications, GenomeWeb reported. In addition, the Life Science Center at Bayer—the European pharma giant that recently made an offer to buy Monsanto—has licensed CRISPR for biomedical uses, but the company’s Crop Science division has not obtained a license for CRISPR/Cas9.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. What Budget Cuts Might Mean for US Science
    News Analysis What Budget Cuts Might Mean for US Science

    A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  

  2. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  3. Opinion: On “The Impact Factor Fallacy”
  4. Unstructured Proteins Help Tardigrades Survive Desiccation
Business Birmingham